Answers are grounded in this paper and cite their sources.
Conventional antimicrobial susceptibility testing, particularly the disc diffusion assay (DDA), provides a convenient means of assessing bacterial susceptibility to antibiotics. However, its ability to predict antibiotic efficacy in an infected host remains uncertain. This study investigated the relationship between DDA-derived inhibition zones and host-protective antibiotic activity using Caenorhabditis elegans infection models involving three bacterial pathogens: methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, and Clostridioides difficile. A total of 42 antibiotics were evaluated through DDA, while a separate panel of 75 antibiotics was screened using an automated C. elegans infection assay. Twenty-six antibiotics common to both panels were selected for comparative analysis. Gnotobiotic L3-L4 stage worms were challenged with individual pathogens in the presence of each antibiotic at a fixed concentration of 9.6 microgram/mL. Worm activity was quantified at 24, 48, and 72 h using an automated worm tracker system, with appropriate health, infection, vehicle, and antibiotic-toxicity controls. Overall, DDA-derived zone of inhibition (ZOI) diameters showed weak-to-moderate, pathogen- and time-dependent correlations with worm activity. At 24 h, Pearson's correlation coefficients ranged from -0.20 to 0.31 across the three pathogen-host systems, while at 48 h they ranged from -0.009 to 0.49. Notably, antibiotic rankings based on DDA and host-protective activity differed considerably. For example, against C. difficile, imipenem produced the largest inhibition zone (41 mm) but failed to protect worms at 24 and 48 h, whereas tobramycin, despite producing a smaller inhibition zone (26 mm), exhibited the highest early worm activity. Similar discrepancies were observed with the other pathogens. These findings demonstrate that DDA-derived susceptibility profiles do not consistently predict antibiotic-mediated protection in an infected host. The C. elegans model may therefore serve as a complementary whole-organism screening platform, providing additional functional information for prioritizing antimicrobial agents beyond conventional in vitro susceptibility testing.
No takes yet. Share an insight, caveat, or question.
Vaghela et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: